Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131

Protein Engineering, Design and Selection

Volumn 26, Issue 10, 2013, Pages 589-598

  Mimoto, F ^a   Katada, H ^a   Kadono, S ^a   Igawa, T ^a   Kuramochi, T ^a   Muraoka, M ^a   Wada, Y ^a   Haraya, K ^a   Miyazaki, T ^a   Hattori, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

antibody engineering; Fc engineering; Fc RIIb; inhibitory Fc R; platelet activation

Indexed keywords

AGONISTIC ACTIVITY; ANTIBODY ENGINEERING; ANTIBODY THERAPEUTICS; BINDING AFFINITIES; CONFORMATIONAL CHANGE; IMMUNE COMPLEX; PLATELET ACTIVATION; PLATELET AGGREGATION;

BINDING ENERGY; CRYSTAL STRUCTURE; PLATELETS;

ANTIBODIES;

CD137 ANTIGEN; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 6 RECEPTOR; RECEPTOR ANTIBODY;

AFFINITY CHROMATOGRAPHY; ALLOTYPE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DISSOCIATION CONSTANT; DISULFIDE BOND; DRUG HALF LIFE; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HEAVY CHAIN; HUMAN; HYDROGEN BOND; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; STATIC ELECTRICITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WILD TYPE;

ANTIBODY ENGINEERING; FC ENGINEERING; FCΓRIIB; INHIBITORY FCΓR; PLATELET ACTIVATION;

ANIMALS; ANTIGENS, CD137; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MODELS, MOLECULAR; MUTAGENESIS; PLATELET ACTIVATION; PLATELET AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 84885007880     PISSN: 17410126     EISSN: 17410134     Source Type: Journal    
DOI: 10.1093/protein/gzt022     Document Type: Article

References (51)

1. Bergtold, A., Desai, D.D., Gavhane, A. and Clynes, R. (2005) Immunity, 23, 503-514.
2. Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V. and Young, J.W. (2005) J. Clin. Invest., 115, 2914-2923.
3. Boumpas, D.T., Furie, R., Manzi, S., Illei, G.G., Wallace, D.J., Balow, J.E. and Vaishnaw, A.; BG9588 Lupus Nephritis Trial Group. (2003) Arthritis Rheum., 48, 719-727.
4. Brekke, O.H. and Sandlie, I. (2003) Nat. Rev. Drug Discov., 2, 52-62.
5. Cemerski, S., Chu, S.Y., Moore, G.L., Muchhal, U.S., Desjarlais, J.R. and Szymkowski, D.E. (2012) Immunol. Lett., 143, 34-43.
6. Chu, S.Y., Vostiar, I., Karki, S., Moore, G.L., Lazar, G.A., Pong, E., Joyce, P.F., Szymkowski, D.E. and Desjarlais, J.R. (2008) Mol. Immunol., 45, 3926-3933.
7. Chu, S.Y., Horton, H.M., Pong, E., et al. (2012) J. Allergy Clin. Immunol., 129, 1102-1115.
8. Crowley, J.E., Stadanlick, J.E., Cambier, J.C. and Cancro, M.P. (2009) Blood, 113, 1464-1473.
9. Dall?Acqua, W.F., Cook, K.E., Damschroder, M.M., Woods, R.M. and Wu, H. (2006) J. Immunol., 177, 1129-1138.
10. DeLano, W.L. (2002) The PyMOL Molecular Graphics System. Palo Alto, CA, Schrodinger, LLC.
11. Desai, D.D., Harbers, S.O., Flores, M., Colonna, L., Downie, M.P., Bergtold, A., Jung, S. and Clynes, R. (2007) J. Immunol., 178, 6217-6226.
12. Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010) Acta Cryst., D66, 486-501.
13. Evans, P. (2006) Acta Cryst., D62, 72-82.
14. Grueninger-Leitch, F., D?Arcy, A., D?Arcy, B. and Chène, C. (1996) Protein Sci., 5, 2617-2622.
15. Hammer, O. (2012) MAbs, 4, 571-577.
16. He, F., Hogan, S., Latypov, R.F., Narhi, L.O. and Razinkov, V.I. (2010) J. Pharm. Sci., 99, 1707-1720.
17. Hernández, T., De Acosta, C.M., López-Requena, A., Moreno, E., Alonso, R., Fernández-Marrero, Y. and Pérez, R. (2010) Mol. Immunol., 48, 98-108.
18. Heyman, B. (2003) Immunol. Lett., 88, 157-161.
19. Horton, H.M., Chu, S.Y., Ortiz, E.C., et al. (2011) J. Immunol., 186, 4223-4233.
20. Igawa, T., Tsunoda, H., Tachibana, T., et al. (2010) Protein Eng. Des. Sel., 23, 385-392.
21. Kabsch, W. (2010) Acta Cryst., D66, 125-132.
22. Lehrnbecher, T., Foster, C.B., Zhu, S., Leitman, S.F., Goldin, L.R., Huppi, K. and Chanock, S.J. (1999) Blood, 94, 4220-4232.
23. Leibson, P.J. (2004) Curr. Opin. Immunol., 16, 328-336.
24. Li, F. and Ravetch, J.V. (2011) Science, 333, 1030-1034.
25. Li, F. and Ravetch, J.V. (2012) Proc. Natl Acad. Sci. USA, 109, 10966-10971.
26. Maggon, K. (2007) Curr. Med. Chem., 14, 1978-1987.
27. Malbec, O. and Daeron, M. (2012) Immunol. Lett., 143, 28-33.
28. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and Read, R.J. (2007) J. Appl. Crystallogr., 40, 658-674.
29. Meyer, T., Robles-Carrillo, L., Robson, T., Langer, F., Desai, H., Davila, M., Amaya, M., Francis, J.L. and Amirkhosravi, A. (2009) J. Thromb. Haemost., 7, 171-181.
30. Mossner, E., Brunker, P., Moser, S., et al. (2010) Blood, 115, 4393-4402.
31. Mousavi, S.A., Sporstøl, M., Fladeby, C., Kjeken, R., Barois, N. and Berg, T. (2007) Hepatology, 46, 871-884.
32. Murshudov, G.N., Skubák, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F. and Vagin, A.A. (2011) Acta Cryst., D67, 355-367.
33. Nimmerjahn, F. and Ravetch, J.V. (2005) Science, 310, 1510-1512.
34. Nimmerjahn, F. and Ravetch, J.V. (2008) Nat. Rev. Immunol., 8, 34-47.
35. Nimmerjahn, F. and Ravetch, J.V. (2012) Cancer Immun., 12, 13.
36. Osborne, J.M., Chacko, G.W., Brandt, J.T. and Anderson, C.L. (1994) J. Immunol. Methods, 173, 207-217.
37. Pollreisz, A., Assinger, A., Hacker, S., et al. (2008) Br. J. Dermatol., 159, 578-584.
38. Ramsland, P.A., Farrugia, W., Bradford, T.M., et al. (2011) J. Immunol., 187, 3208-3217.
39. Richards, J.O., Karki, S., Lazar, G.A., Chen, H., Dang, W. and Desjarlais, J.R. (2008) Mol. Cancer Ther., 7, 2517-2527.
40. Robles-Carrillo, L., Meyer, T., Hatfield, M., et al. (2010) J. Immunol., 185, 1577-1583.
41. Scappaticci, F.A., Skillings, J.R., Holden, S.N., et al. (2007) J. Natl Cancer Inst., 99, 1232-1239.
42. Shuford, W.W., Klussman, K., Tritchler, D.D., et al. (1997) J. Exp. Med., 186, 47-55.
43. Smith, P., DiLillo, D.J., Bournazos, S., Li, F. and Ravetch, J.V. (2012) Proc. Natl Acad. Sci. USA, 109, 6181-6186.
44. Stavenhagen, J.B., Gorlatov, S., Tuaillon, N., et al. (2007) Cancer Res., 67, 8882-8890.
45. White, A.L., Chan, H.T., Roghanian, A., et al. (2011) J. Immunol., 187, 1754-1763.
46. White, A.L., Chan, H.T., French, R.R., Beers, S.A., Cragg, M.S., Johnson, P.W. and Glennie, M.J. (2013) Cancer Immunol Immunother., 62, 941-948.
47. Wilson, N.S., Yang, B., Yang, A., et al. (2011) Cancer Cell, 19, 101-113.
48. Winter, G. (2010) J. Appl. Cryst., 43, 186-190.
49. Zalevsky, J., Leung, I.W., Karki, S., Chu, S.Y., Zhukovsky, E.A., Desjarlais, J.R., Carmichael, D.F. and Lawrence, C.E. (2009) Blood, 113, 3735-3743.
50. Zhang, C.Y. and Booth, J.W. (2010) J. Biol. Chem., 285, 34250-34258.
51. Zhang, Y., Liu, S., Yu, Y., Zhang, T., Liu, J., Shen, Q. and Cao, X. (2011) Eur. J. Immunol., 41, 1154-1164.